Publications

Export 43 results:
Auteur Title [ Type(Asc)] Année
Filtres: Auteur is Judes Poirier  [Enlever les filtres]
Journal Article
Benedet AL, Yu L, Labbe A, Mathotaarachchi S, Pascoal TA, Shin M, Kang M-S, Gauthier S, Rouleau GA, Poirier J et al..  2018.   variant mitigates Alzheimer disease pathophysiology in vivo and postmortem.. Neurol Genet. 4(1):e216.
Miron J, Picard C, Frappier J, Dea D, Théroux L, Poirier J.  2018.  TLR4 Gene Expression and Pro-Inflammatory Cytokines in Alzheimer's Disease and in Response to Hippocampal Deafferentation in Rodents.. J Alzheimers Dis. 63(4):1547-1556.
Schoemaker D, Poirier J, Escobar S, Gauthier S, Pruessner J.  2016.  Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease.. Alzheimers Dement (Amst). 2:132-9.
Leduc V, Bourque L, Poirier J, Dufour R.  2016.  Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia.. Pharmacogenet Genomics. 26(1):1-11.
Tardif CL, Devenyi GA, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner JCS, M Chakravarty M.  2018.  Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.. Hum Brain Mapp. 39(2):971-984.
Breitner JCS, Poirier J, Etienne PE, Leoutsakos JM.  2016.  Rationale and Structure for a New Center for Studies on Prevention of Alzheimer's Disease (StoP-AD).. J Prev Alzheimers Dis. 3(4):236-242.
Villeneuve S, Vogel JW, Gonneaud J, Binette APichet, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS et al..  2018.  Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease.. JAMA Neurol.
Picard C, Poirier A, Bélanger S, Labonte A, Auld D, Poirier J.  2019.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study.. PLoS One. 14(8):e0220254.
Lafaille-Magnan M-E, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS.  2017.  Odor identification as a biomarker of preclinical AD in older adults at risk.. Neurology. 89(4):327-335.
Meyer P-F, Labonte A, Rosa-Neto P, Poirier J, Breitner JCS.  2019.  No apparent effect of naproxen on CSF markers of innate immune activation.. Ann Clin Transl Neurol. 6(6):1127-1133.
De Schutter JW, Park J, Leung CYuen, Gormley P, Lin Y-S, Hu Z, Berghuis AM, Poirier J, Tsantrizos YS.  2014.  Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.. J Med Chem. 57(13):5764-76.
Parent MJ, Zimmer ER, Shin M, Kang MSu, Fonov VS, Mathieu A, Aliaga A, Kostikov A, Carmo SDo, Dea D et al..  2017.  Multimodal Imaging in Rat Model Recapitulates Alzheimer's Disease Biomarkers Abnormalities.. J Neurosci. 37(50):12263-12271.
Paquette M, Saavedra YGrisel Lun, Poirier J, Théroux L, Dea D, Baass A, Dufour R.  2018.  Loss-of-Function PCSK9 Mutations Are Not Associated With Alzheimer Disease.. J Geriatr Psychiatry Neurol. 31(2):90-96.
Lleó A, Alcolea D, Martínez-Lage P, Scheltens P, Parnetti L, Poirier J, Simonsen AH, Verbeek MM, Rosa-Neto P, Slot RER et al..  2019.  Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.. Alzheimers Dement. 15(6):742-753.
Pelleieux S, Picard C, Lamarre-Théroux L, Dea D, Leduc V, Tsantrizos YS, Poirier J.  2018.  Isoprenoids and tau pathology in sporadic Alzheimer's disease.. Neurobiol Aging. 65:132-139.
Meyer P-F, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan M-É, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner JCS.  2019.  INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.. Neurology. 92(18):e2070-e2080.
Meyer P-F, Savard M, Poirier J, Morgan D, Breitner JCS.  2019.  Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology.. Alzheimers Dement. 15(9):1160-1171.
Leduc V, De Beaumont L, Théroux L, Dea D, Aisen P, Petersen RC, Dufour R, Poirier J.  2015.  HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.. Mol Psychiatry. 20(7):867-73.
Konishi K, Joober R, Poirier J, MacDonald K, M Chakravarty M, Patel R, Breitner JCS, Bohbot VD.  2018.  Healthy versus Entorhinal Cortical Atrophy Identification in Asymptomatic APOE4 Carriers at Risk for Alzheimer's Disease.. J Alzheimers Dis. 61(4):1493-1507.
Schoemaker D, Poirier J, D Collins L, Gauthier S, Pruessner JC.  2017.  Familiarity deficits in cognitively normal aging individuals with APOE ε4: A follow-up investigation of medial temporal lobe structural correlates.. Alzheimers Dement (Amst). 9:21-24.
Benedet AL, Labbe A, Lemay P, Zimmer ER, Pascoal TA, Leuzy A, Mathotaarachchi S, Mohades S, Shin M, Dionne-Laporte A et al..  2015.  Epistasis analysis links immune cascades and cerebral amyloidosis.. J Neuroinflammation. 12:227.
Leduc V, Théroux L, Dea D, Dufour R, Poirier J.  2016.  Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology.. J Mol Neurosci. 58(1):109-19.
Jasmin SBélanger, Pearson V, Lalonde D, Domenger D, Théroux L, Poirier J.  2014.  Differential regulation of ABCA1 and ABCG1 gene expressions in the remodeling mouse hippocampus after entorhinal cortex lesion and liver-X receptor agonist treatment.. Brain Res. 1562:39-51.
Gan-Or, iv Z, Montplaisir JY, Ross JP, Poirier J, Warby SC, Arnulf I, Strong S, Dauvilliers Y, Leblond CS, Hu MTM et al..  2017.  The dementia-associated APOE ε4 allele is not associated with rapid eye movement sleep behavior disorder.. Neurobiol Aging. 49:218.e13-218.e15.
Tuwaig M, Savard M, Jutras B, Poirier J, D Collins L, Rosa-Neto P, Fontaine D, Breitner JCS.  2017.  Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer's Disease.. J Alzheimers Dis. 60(4):1589-1600.

Pages